AOD-9604 Metabolic
Key Finding
Reviewed AOD-9604's metabolic profile and fat-reducing properties, confirming its ability to stimulate lipolysis and inhibit lipogenesis without adverse growth hormone effects.
Key Takeaways
- AOD-9604 breaks down existing fat and stops new fat from forming.
- It does this without causing fluid retention, joint pain, or insulin issues.
- It offers the fat-loss benefits of growth hormone without the downsides.
Study Breakdown
Understanding the specific metabolic mechanisms through which AOD-9604 affects fat metabolism is essential for appreciating its unique therapeutic value. This review by Wilding examined AOD-9604's metabolic profile and its dual action on fat metabolism pathways.
The author analyzed the available evidence on AOD-9604's effects on lipid metabolism, examining both its lipolytic activity (fat breakdown) and its anti-lipogenic effects (inhibition of fat formation). The review also assessed the peptide's safety profile, particularly regarding potential growth hormone-related side effects.
The review confirmed that AOD-9604 effectively stimulates lipolysis and inhibits lipogenesis, achieving a dual-action effect on fat metabolism. Critically, it accomplishes this without the adverse growth hormone effects such as fluid retention, insulin resistance, or joint pain that can accompany full growth hormone therapy.
For patients seeking targeted fat reduction, AOD-9604's confirmed ability to both break down existing fat and prevent new fat formation represents an appealing dual mechanism. The absence of growth hormone-related side effects makes it a particularly attractive option for individuals who want the fat-metabolizing benefits of the growth hormone pathway without its broader systemic effects.
Read the full study on PubMed for complete methodology, data, and citations.
View Full Study on PubMedPMID: 15134286
About AOD-9604
A modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the growth-promoting or diabetogenic effects of full-length HGH.
Learn more about AOD-9604 →More AOD-9604 Research
Obesity drugs in clinical development
Halford JC — Current opinion in investigational drugs (London, England : 2000) · 2006 Apr
Gateways to clinical trials
Bayes M, Rabasseda X, Prous JR — Methods and findings in experimental and clinical pharmacology · 2005 Apr
AOD-9604 does not influence the WADA hGH isoform immunoassay
Orlovius AK, Thomas A, Schanzer W, et al. — Drug testing and analysis · 2013 Nov-Dec
Interested in how this research applies to your health goals?
Consult Dr. TaylorDisclaimer: This summary is for educational purposes only and is not medical advice. The study breakdown is a simplified overview of the published research. For complete methodology and data, refer to the original publication on PubMed. Always consult with a qualified healthcare provider before making medical decisions.